Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Chordoma × Pemetrexed × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 249 Lung Neoplasms 95 Adenocarcinoma of Lung 24 Mesothelioma, Malignant 21 Neoplasms 18 Neoplasm Metastasis 15 Breast Neoplasms 11 Brain Neoplasms 11 Mesothelioma 10 Head and Neck Neoplasms 8 Recurrence 7 Colorectal Neoplasms 7 Ovarian Neoplasms 6 Adenocarcinoma, Bronchiolo-Alveolar 6 Adenocarcinoma 6 Small Cell Lung Carcinoma 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 Meningeal Carcinomatosis 5 Squamous Cell Carcinoma of Head and Neck 4 Solitary Fibrous Tumor, Pleural 4 Sarcoma 4 NSCLC 4 Carcinoma 4 Uterine Cervical Neoplasms 3 Urinary Bladder Neoplasms 3 Pancreatic Neoplasms 3 Lung Diseases 3 Carcinoma, Transitional Cell 3 Carcinoma, Small Cell 3 Uterine Neoplasms 2

Interventions

Nivolumab 3 palbociclib 2 Ipilimumab 2 Imatinib Mesylate 2 relatlimab 1 pembrolizumab 1 camrelizumab 1 apatinib 1 Specimen Handling 1 Radiotherapy 1 Radiation 1 Protons 1 Proton Therapy 1 Pemetrexed 1 Magnetic Resonance Spectroscopy 1 Immunoglobulin G 1 Disulfides 1 Dasatinib 1 Cetuximab 1 CTLA-4 Antigen 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06794645 2025-01-27

Pembrolizumab and Pemetrexed for Progressive Chordoma

Saint John's Cancer Institute

Phase 2 Recruiting

Chordoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡